Plasma tau biomarkers for biological staging of Alzheimer’s disease
Laia Montoliu‐Gaya(Sahlgrenska University Hospital), Oskar Hansson(Eli Lilly (United States)), Gunnar Brinkmalm(University of Gothenburg), Sebastian Palmqvist(Skåne University Hospital), Erik Stomrud(Lund University), Kaj Blennow(Sahlgrenska University Hospital), Juan Lantero‐Rodriguez(University of Gothenburg), Sophia Weiner(Institute of Neurobiology), Niklas Mattsson(Malmö University), Nesrine Rahmouni(McGill University), Andréa Lessa Benedet(University of Pittsburgh), Gemma Salvadó(Lund University), Johanna Nilsson(University of Gothenburg), Henrik Zetterberg(University of Wisconsin–Madison), Shorena Janelidze(Lund University), Pedro Rosa‐Neto(Center for Diagnosis and Research on Alzheimer's Disease), Johan Gobom(Sahlgrenska University Hospital), Nicholas J. Ashton(King's College London), Joseph Therriault(Douglas Mental Health University Institute)
Cited by 17
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
|Alzheimer s & Dementia|2024|2.3k
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
|New England Journal of Medicine|2014|2k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
|Alzheimer s & Dementia|2016|1.9k